{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-141341","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.137778+00:00","generated_at":"2026-06-25T23:53:27.875425+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AlloVir Q1 net loss $43.9M; advances posoleucel to Phase 3 multi-virus prevention","bullets":["Net loss $43.9M ($0.69/share) vs $30.9M ($0.50) in Q1 2021; R&D spend $29.1M.","Cash, equivalents & marketable securities $201.4M, down from $248.1M at year-end 2021.","Initiated global Phase 3 registrational study of posoleucel to prevent 6 viruses in allo-HCT patients.","FDA granted third RMAT designation for posoleucel multi-virus prevention; estimated addressable population 40,000 patients/year.","FY2022 operating expense guidance reaffirmed at $130M–$145M excluding stock-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-141341","json":"https://secwatch.observer/filing/0001193125-22-141341.json","markdown":"https://secwatch.observer/filing/0001193125-22-141341.md","text":"https://secwatch.observer/filing/0001193125-22-141341.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522141341/0001193125-22-141341-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522141341/d339026d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:53:27.875425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}